Die Suchmaschine für Unternehmensdaten in Europa
UK-Förderung (1.120.232 £): Antikörper entfesselt: Kühlkettenfreie und patientenfreundliche Therapien Ukri01.02.2025 Forschung und Innovation im Vereinigten Königreich, Großbritannien
Auf einen Blick
Text
Antikörper entfesselt: Kühlkettenfreie und patientenfreundliche Therapien
| Zusammenfassung | Currently antibody medicines require ultra-cold-chain during production and storage to prevent spoiling due to aggregation at the molecular level, which can occur at any stage from factory to patient. This project uses game-changing, proprietary Ensilication technology to remove this cold-chain dependence in the manufacturing and supply of antibody treatments. Ensilication technology will: * reduce product losses during manufacturing, * eliminate cold-chain costs and wastages during transport and storage. Additionally, there are potential patient benefits as ensilication supports antibody therapies to be reformulated for lower volume/higher concentration, allowing a move from intravenous to subcutaneous administration in the community/home rather than clinic settings. EnsiliTech and CPI will demonstrate the implementation of the Ensilication process for antibody production and will perform comprehensive analysis and comparison of COGS with ensilication addition. **Cold-chain logistics for antibody transport and storage** Most antibodies require cold-chain logistics, with most therapeutic antibodies needing ultra-cold storage (-80°C) due to their aggregation propensity. Cold-chain failures are expensive, costing the biopharmaceutical industry $35 billion annually. Cold-chain infrastructure is also challenging in low and middle-income countries (LMICs) making antibody treatments less accessible. **Antibody aggregation and easier subcutaneous administration** Antibodies are prone to aggregation, resulting in low product concentration and frozen storage. Most are administered intravenously in hospitals, inconveniencing patient experience with long injection times. Ensilication prevents antibody aggregation and allows for increased concentration in smaller volumes, which can enable reformulation for subcutaneous administration. This technology enhances ease of administration by reducing the physical volume of antibody treatments, removing aggregation and allowing for room-temperature stability. The project leverages the growing trend of reformulating intravenous antibody treatments for **subcutaneous administration**, which is less invasive, more convenient, and can be administered in community or home settings. **Impact of the Project** **Sustainability and Accessibility**: By removing the dependency on cold-chain logistics and improving antibody stability and administration, the project will significantly reduce costs and improve treatment access, especially in LMICs. **Scalability**: The manufacturing process developed for ensilicated antibodies is applicable to other products, creating a platform for the production of thermally-stable antibody therapies and other biopharmaceuticals. **Healthcare and Ecological Benefits**: The project reduces the environmental and economic burden of cold-chain logistics and hospital-based administration while improving patient access to advanced antibody therapies. Moving treatments to community settings will also alleviate pressure on healthcare systems. The intellectual property generated will be licensed to manufacturers, enabling sustainable production and broader distribution of antibody therapies across the globe. |
| Kategorie | Collaborative R&D |
| Referenz | 10143217 |
| Status | Active |
| Laufzeit von | 01.02.2025 |
| Laufzeit bis | 31.01.2027 |
| Fördersumme | 1.120.232,00 £ |
| Quelle | https://gtr.ukri.org/projects?ref=10143217 |
Beteiligte Organisationen
| ENSILICATED TECHNOLOGIES LTD |
712.054,00 £ |
| CENTRE FOR PROCESS INNOVATION LIMITED |
408.178,00 £ |
Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Ensilicated Technologies Ltd., Bristol, Großbritannien.
Die Visualisierungen zu "Ensilicated Technologies Ltd. - UK-Förderung (1.120.232 £): Antikörper entfesselt: Kühlkettenfreie und patientenfreundliche Therapien"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
